MILWAUKEE, Oct. 9, 2025 /PRNewswire/ — The Ademi Firm is investigating Akero (NASDAQ: AKRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk.
Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.
Shareholders of Akero will receive $54.00 per share, representing an equity value of approximately $4.7 billion. Shareholders will also receive a contingent value right entitling them to an additional $6.00 per share if Akero’s drug efruxifermin receives full U.S. regulatory approval for treating compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis by June 30, 2031.
Akero insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Akero by imposing a significant penalty if Akero accepts a competing bid. We are investigating the conduct of the Akero board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi & Fruchter LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In